Cargando…

Moving targets: COVID-19 vaccine efficacy against Omicron subvariants

Detalles Bibliográficos
Autores principales:	da Silva, Maria Karolaynne, Fulco, Umberto Laino, Júnior, Edilson Dantas da Silva, Oliveira, Jonas Ivan Nobre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339136/ https://www.ncbi.nlm.nih.gov/pubmed/35914527 http://dx.doi.org/10.1016/j.ymthe.2022.07.004

Ejemplares similares

Beyond pharmaceuticals: The untapped potential of homeopathy in the battle against COVID-19
por: de Farias Morais, Gabriel Christian, et al.
Publicado: (2023)

Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants
por: Campos, Daniel Melo de Oliveira, et al.
Publicado: (2022)

Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools
por: da Silva, Maria Karolaynne, et al.
Publicado: (2023)

Redundancy of Terms in Search Strategies. Comment on “Searching PubMed to Retrieve Publications on the COVID-19 Pandemic: Comparative Analysis of Search Strings”
por: Campos, Daniel Melo De Oliveira, et al.
Publicado: (2021)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic
por: da Silva, Severino Jefferson Ribeiro
Publicado: (2022)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C. Paul, et al.
Publicado: (2022)

Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
por: Morris, C Paul, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
por: Machado, Rafael R. G., et al.
Publicado: (2023)

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
por: Moriyama, Miyu, et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients
por: Chen, Jun, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Omicron subvariant BA.5 efficiently infects lung cells
por: Hoffmann, Markus, et al.
Publicado: (2023)

Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
por: Li, Yaning, et al.
Publicado: (2023)

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
por: Desautels, Thomas A., et al.
Publicado: (2023)

Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children
por: Li, Xiaohe, et al.
Publicado: (2022)

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
por: Cho, Junhyung, et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

The link between vitamin D and COVID-19
por: Campos, Daniel M.O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9o64rjit20jtpki7vqf40j14tt